| Literature DB >> 29450174 |
Kadriye Kilickesmez1, Gianni Dall'Ara1, Juan Carlos Rama-Merchan1, Matteo Ghione1, Alessio Mattesini1, Carlos Moreno Vinues1, Nikolaos Konstantinidis1, Michele Pighi1, Rodrigo Estevez-Loureiro1, Carlo Zivelonghi1, Alistair C Lindsay1, Gioel G Secco1,2, Nicolas Foin3, Ranil De Silva1,3, Carlo Di Mario1,3.
Abstract
AIMS: Characterization of neointimal tissue is essential to understand the pathophysiology of in-stent restenosis (ISR) after drug eluting stent (DES) implantation. Using optical coherence tomography (OCT), we compared the morphologic characteristics of ISR between first and second generation DES. METHODS ANDEntities:
Keywords: Drug eluting stent; In-stent restenosis; Neoatherosclerosis; Optical coherence tomography
Year: 2014 PMID: 29450174 PMCID: PMC5801271 DOI: 10.1016/j.ijchv.2014.03.003
Source DB: PubMed Journal: Int J Cardiol Heart Vessel ISSN: 2214-7632
Fig. 1Quantitative optical coherence tomography analysis. Representation of measured areas. CSA: cross sectional area; NIH: neointimal hyperplasia.
Fig. 2Qualitative optical coherence tomography analysis. For definitions, refer in the text. 1) Homogeneous pattern of ISR. 2) Heterogeneous patterns subsequently subdivided in three subtypes: 2a) layered pattern; 2b) patchy pattern; and 2c) speckled pattern. 3) Neo-atherosclerosis and its main features: 3a) lipid plaque; 3b) calcium deposit; 3c) thin-cap fibro-atheroma; and 3d) detail of macrophage presence in a lipid plaque. 4) Miscellaneous ISR characteristics: 4a) microvessels; 4b) peri-strut low intensity areas; 4c) overlapping stents; and 4d) malapposed struts.
Fig. 3Schematic view of enrolled stents, according to generation, eluted drug and brand. For acronyms see “Results” chapter.
Baseline clinical characteristics, analysis per patients.
| Variable | First generation (n = 30) | p | Second generation (n = 11) | p | p* | p** | ||
|---|---|---|---|---|---|---|---|---|
| ≤ 1 year (n = 9) | > 1 year (n = 21) | ≤ 1 year (n = 7) | > 1 year (n = 4) | |||||
| Males | 8 (88.9) | 18 (85.7) | 0.81 | 6 (85.7) | 4 (100.0) | 0.43 | 0.85 | 0.42 |
| Age, years | 63.9 ± 7.1 | 69.7 ± 8.7 | 0.09 | 67.9 ± 17.3 | 61.7 ± 7.4 | 0.52 | 0.54 | 0.10 |
| Diabetes | 3 (33.3) | 7 (33.3) | NA | 5 (71.4) | 1 (25.0) | 0.14 | 0.13 | 0.74 |
| Hypertension | 7 (77.8) | 17 (81.0) | 0.84 | 6 (85.7) | 3 (75.0) | 0.66 | 0.69 | 0.79 |
| High cholesterol | 9 (100.0) | 18 (85.7) | 0.23 | 7 (100.0) | 4 (100.0) | NA | NA | 0.42 |
| History of CAD | 6 (66.7) | 11 (52.4) | 0.69 | 4 (57.1) | 3 (75.0) | 0.55 | 0.70 | 0.40 |
| Current smoker | 3 (33.3) | 8 (38.1) | 0.80 | 4 (57.1) | 2 (50.0) | 0.82 | 0.34 | 0.66 |
| Previous CABG | 3 (33.3) | 10 (47.6) | 0.69 | 5 (71.4) | 1 (50.0) | 0.48 | 0.13 | 0.93 |
| Previous MI | 6 (75.0) | 14 (73.7) | 0.94 | 2 (33.3) | 4 (100.0) | 0.04 | 0.12 | 0.25 |
| Indication to PCI | ||||||||
| Stable angina | 3 (33.3) | 11 (52.4) | 0.34 | 4 (57.1) | 2 (50.0) | 0.82 | 0.34 | 0.93 |
| ACS | 0 (0.0) | 4 (19.0) | 0.16 | 0 (0.0) | 0 (0.0) | NA | NA | 0.34 |
| Planned follow-up | 6 (66.7) | 6 (28.6) | 0.10 | 3 (42.9) | 2 (50.0) | 0.82 | 0.34 | 0.40 |
| Vessel with ISR | 0 (0.0) | 1 (4.8) | 0.51 | 0 (0.0) | 0 (0.0) | NA | NA | 0.65 |
| LM | 3 (33.3) | 8 (38.1) | 0.80 | 2 (28.6) | 2 (50.0) | 0.48 | 0.84 | 0.66 |
| LAD | 4 (44.4) | 7 (33.3) | 0.69 | 0 (0.0) | 1 (25.0) | 0.17 | 0.04 | 0.74 |
| LCX | 2 (22.2) | 2 (9.5) | 0.35 | 2 (28.6) | 1 (25.0) | 0.89 | 0.77 | 0.38 |
| RCA | 0 (0.0) | 1 (4.8) | 0.51 | 0 (0.0) | 0 (0.0) | NA | NA | 0.67 |
| LIMA | 0 (0.0) | 2 (9.5) | 0.34 | 3 (42.9) | 0 (0.0) | 0.13 | 0.03 | 0.52 |
| Venous graft | ||||||||
| Medications | 8 (88.9) | 17 (85.0) | 0.78 | 5 (71.4) | 2 (66.7) | 0.88 | 0.38 | 0.44 |
| Statin | 1 (11.1) | 12 (60.0) | 0.01 | 5 (71.4) | 0 (0.0) | 0.04 | 0.01 | 0.05 |
| ACE-I | 9 (100.0) | 20 (100.0) | NA | 7 (100.0) | 3 (100.0) | NA | NA | NA |
| ASA | ||||||||
Continuous variables are expressed as the mean ± SD; categorical variables as number (%). ACE-I: angiotensin convertor enzyme inhibitor; ACS: acute coronary syndrome; ASA: acetyl salicylic acid; CABG: coronary artery bypass graft; CAD: coronary artery disease; ISR: in-stent restenosis; LAD: left anterior descending artery; LCX: left circumflex; LIMA: left internal mammary artery; LM: left main artery; MI: myocardial infarction; OCT: optical coherence tomography; RCA: right coronary artery. p: comparison within each DES generation; p*:comparison of early ISR between generations; p**: comparison of late ISR between generations.
Angiographic and QCA data, analysis per lesion.
| Variable | First generation (n = 44) | p | Second generation (n = 22) | p | p* | p** | ||
|---|---|---|---|---|---|---|---|---|
| ≤ 1 year (n = 13) | > 1 year (n = 31) | ≤ 1 year (n = 14) | > 1 year (n = 8) | |||||
| Restenosis pattern | ||||||||
| Focal | 11 (84.6) | 20 (64.5) | 0.28 | 5 (35.7) | 7 (87.5) | 0.02 | 0.02 | 0.40 |
| Diffuse | 2 (15.4) | 11 (35.5) | 0.28 | 9 (64.3) | 1 (12.5) | 0.02 | 0.03 | 0.40 |
| QCA data | ||||||||
| Lesion length, mm | 7.7 ± 4.5 | 12.2 ± 8.8 | 0.09 | 18.7 ± 14.4 | 7.5 ± 3.6 | 0.01 | 0.02 | 0.15 |
| RD, mm | 2.9 ± 0.6 | 3.0 ± 0.7 | 0.48 | 3.0 ± 0.6 | 3.0 ± 0.8 | 0.89 | 0.65 | 0.98 |
| MLD, mm | 1.1 ± 0.6 | 1.0 ± 0.5 | 0.75 | 0.8 ± 0.4 | 1.4 ± 0.5 | < 0.01 | 0.12 | 0.07 |
| MLA, mm2 | 1.2 ± 0.9 | 1.3 ± 1.9 | 0.80 | 0.6 ± 0.5 | 1.6 ± 1.2 | < 0.01 | 0.06 | 0.65 |
| Diameter stenosis, % | 64.0 ± 16.2 | 67.0 ± 15.7 | 0.63 | 71.7 ± 16.2 | 54.4 ± 7.1 | < 0.01 | 0.22 | < 0.01 |
| Stent type | ||||||||
| Cypher | 5 (38.5) | 16 (51.6) | 0.52 | – | – | 0.09 | NA | NA |
| Taxus | 8 (61.5) | 15 (48.4) | – | – | ||||
| Xience | – | – | 3 (21.4) | 6 (75.0) | ||||
| Promus | – | – | 2 (14.3) | 0 (0.0) | ||||
| Resolute | – | – | 8 (57.1) | 2 (25) | ||||
| BioMatrix | – | – | 1 (7.1) | 0 (0.0) | ||||
| Time from previous stent to ISR | 10.0 ± 2.8 | 37.0 ± 18.3 | < 0.01 | 8.1 ± 3.1 | 15.8 ± 4.0 | < 0.01 | 0.12 | < 0.01 |
Continuous variables are expressed as the mean ± SD; categorical variables as number (%). ISR: in-stent restenosis; MLA: minimal lumen area; MLD: minimal lumen diameter; QCA: quantitative coronary analysis. RD: reference diameter; p: comparison within each DES generation; p*: comparison of early ISR between generations; p**: comparison of late ISR between generations.
Quantitative OCT analysis per cross-section with ISR > 50%.
| Variable | First generation (n = 143) | p | Second generation (n = 89) | p | p* | p** | ||
|---|---|---|---|---|---|---|---|---|
| ≤ 1 year (n = 43) | > 1 year (n = 100) | ≤ 1 year (n = 70) | > 1 year (n = 19) | |||||
| Mean stent CSA, mm2 | 5.0 ± 2.1 | 5.1 ± 1.7 | 0.88 | 8.4 ± 3.2 | 4.3 ± 1.1 | < 0.01 | < 0.01 | 0.01 |
| Mean lumen CSA, mm2 | 1.6 ± 1.3 | 1.6 ± 1.2 | 0.86 | 3.2 ± 1.3 | 1.9 ± 0.5 | < 0.01 | < 0.01 | 0.08 |
| NHI CSA, mm2 | 3.5 ± 1.0 | 3.5 ± 0.9 | 0.91 | 5.2 ± 2.4 | 2.4 ± 0.7 | < 0.01 | < 0.01 | < 0.01 |
| NIH area, % | 72.1 ± 12.1 | 71.4 ± 14.9 | 0.79 | 61.1 ± 8.4 | 55.5 ± 5.2 | < 0.01 | < 0.01 | < 0.01 |
| Restenosis length, mm | 7.1 ± 11.9 | 5.3 ± 6.7 | 0.62 | 6.4 ± 6.4 | 4.7 ± 2.5 | 0.50 | 0.86 | 0.88 |
Continuous variables are expressed as the mean ± SD. CSA: cross sectional area; NIH: neo-intimal hyperplasia. p: comparison within each DES generation; p*: comparison of early ISR between generations; p**: comparison of late ISR between generations.
OCT qualitative analysis in the entire stent.
| Variable | First generation (n = 1036) | p | Second generation (n = 641) | p | p* | p** | ||
|---|---|---|---|---|---|---|---|---|
| ≤ 1 year (n = 309) | > 1 year (n = 727) | ≤ 1 year (n = 496) | > 1 year (n = 145) | |||||
| Homogeneous | 132 (42.7) | 515 (70.8) | < 0.01 | 155 (31.2) | 32 (22.1) | 0.04 | < 0.01 | < 0.01 |
| Heterogeneous | 117 (37.9) | 161 (22.2) | < 0.01 | 283 (57.1) | 85 (58.6) | 0.70 | < 0.01 | < 0.01 |
| Layered | 9 (7.7) | 69 (42.9) | 40 (14.1) | 26 (31.7) | ||||
| Patchy | 87 (75.0) | 74 (46.0) | 211 (7.5) | 5 0(58.8) | ||||
| Speckled | 21 (18.1) | 18 (11.2) | 32 (11.3) | 9 (10.6) | ||||
| Neo-atherosclerosis | 60 (19.4) | 51 (7.0) | < 0.01 | 58(11.7) | 28(19.3) | 0.01 | < 0.01 | < 0.01 |
| Lipids | 59 (19.1) | 34 (4.7) | < 0.01 | 49 (9.9) | 26 (17.9) | 0.01 | < 0.01 | < 0.01 |
| Calcium | 20 (6.5) | 10 (1.4) | < 0.01 | 7 (1.4) | 4 (2.8) | 0.28 | < 0.01 | 0.27 |
| TCFA | 3 (1.0) | 7 (1.0) | 0.99 | 2 (0.4) | 0 (0.0) | 0.98 | 0.32 | 0.61 |
| Macrophages | 3 (1.0) | 6 (0.8) | 0.73 | 3 (0.6) | 0 (0.0) | 0.35 | 0.56 | 0.60 |
| Microvessels | 8 (2.6) | 2 (0.3) | < 0.01 | 1 (0.2) | 1 (0.7) | 0.35 | < 0.01 | 0.44 |
| PSLIA | 48 (15.5) | 65 (8.9) | < 0.01 | 57 (11.5) | 39 (26.9) | < 0.01 | 0.11 | < 0.01 |
| Overlapping CSs | 31 (10.0) | 65 (8.9) | 0.56 | 36 (7.3) | 11 (7.6) | 0.86 | 0.19 | 0.75 |
| Malapposed struts | 0 (0.0) | 12 (1.7) | 0.08 | 4 (0.8) | 1 (0.7) | 0.89 | 0.11 | 0.65 |
| Uncovered struts | 3 (1.0) | 22 (3.0) | 0.04 | 15 (3.0) | 2 (1.4) | 0.39 | 0.08 | 0.41 |
Categorical variables are expressed as number (%). CSs: cross-sections; OCT: optical coherence tomography; PSLIA: peri-strut low intensity area. p: comparison within each DES generation; p*: comparison of early ISR between generations; p**: comparison of late ISR between generations.
Fig. 4Absolute prevalence of the main optical patterns of in-stent restenosis according to DES generations and early or late phase of follow-up. For statistical significance refer to Table 4.